Stocks made a third attempt at a rally Thurdsay though techs took a beating amid worries about the outlook for the sector.
A rally spurred by bargain hunting fizzled Thursday as weakness in technology leaders offset strength energy-related companies.
Stocks are trapped in a volatile selling wave, driven by fears of the weakening global economy even as credit markets continue to show signs of improvement.
With so many other factors powering the market these days, third-quarter earnings could be little more than an afterthought.
A drug stock with a safe dividend? That's just what you need in this tough environment.
I don't think Eli Lilly will be running any more "Coming Soon" ads--like the one posted here for its late-stage experimental bloodthinner Effient--for drugs that haven't been approved yet by the Food and Drug Administration.
In my reporting, I always try to keep it simple. Particularly in the middle of the credit crisis, too much financial jargon goes over the heads of most people. The same can be said for biopharma coverage.
The Dow pared its massive loss in the final hour of trading Monday after fear that the credit crisis is spreading rippled through world markets. The blue-chip index ended down about 370 points, after being down as much as 800 at one point.
Pretty much all of biopharma is caught in the downdraft of the markets today with the notable exception of Dendreon (data) and ImClone Systems (a deal).
The Dow dropped below 9,600 Monday after global markets took a pounding amid fear that the credit crisis is spreading around the globe.
The Dow dropped below 9,900 Monday after global markets took a pounding amid fear that the credit crisis is spreading around the globe.
Okay, what were the chances that ImClone would get bought and Dendreon would come out with its interim test results on the same morning? Slim to none, I'd say. But that's exactly what the news gods had in store for two of the hottest names in biotech.
The Dow dropped below 10000 Monday after global markets took a pounding amid fear that the credit crisis is spreading around the globe.
Wall Street was set to plunge at the open Monday as a $700 billion plan approved by Congress on Friday failed to restore confidence in the global banking system.
For the week ending Friday, October 3, 2008, the major U.S. Indices declined steeply on continued uncertainties over the financial bailout / rescue plan, concerns in the credit markets and more economic deterioration.
Plus, Cramer speculates on where the shorts could hit next.
Maria Bartiromo discusses Thursday's top business and financial stories, and looks ahead to tomorrow's events.
"The Wall Street Journal" unmasked the identity--Eli Lilly--of ImClone's secret suitor. A spokesman for LLY said he couldn't confirm or deny the report. IMCL put out a press release last night saying that the mystery bidder has asked to remain anonymous.
Congressional leaders "sweeten" the $700 billion financial rescue package to attract enough House members, particularly Republicans, to pass the plan that failed in the House just two days ago. In the meantime, billionaire investor Warren Buffett takes opportunity of the rocky markets to invest $3 Billion in GE, the parent company of CNBC. Following are today's top videos:
The Dow closed lower on Wednesday as nervous investors found it difficult to muster enthusiasm ahead of the Senate’s vote on a revamped $700 billion rescue plan.